JEEP — orange-cap Tirzepatide T30, January 2026 batch

The most-documented batch-quality failure in our 2026 corpus. Endotoxin contamination on injection-grade product, found across three independently-sourced vials from different countries.

On who ran the test. The assays were run by Janoshik. “LS Group Testing” is the community group-buy cohort that organised, funded and submitted the samples, not a laboratory; the submission is logged at Janoshik under the client name “EPU x LS Group Testing GB x juGGakNot Empire”. An earlier version of this entry named LS as the testing lab in one place and LiquiLabs in another. Both were wrong, and we have corrected them.

JEEP (also seen written as “JEEPJEEP” in vendor-side communications, branded around a sales rep called “Molly JEEP” on glp1forum.com) is a China-based research peptide vendor that maintains an active vendor account in the GLP-1 Forum marketplace. Through 2025 and into early 2026, JEEP ran the standard vendor-sponsor playbook: holiday-sale announcement threads, promo discount codes, customer-testimonial replies. Volume was high enough that the vendor was treated as mainstream-trustworthy by a meaningful slice of the community.

Timeline: - January 2026 — JEEP ships orange-cap Tirzepatide 30mg (“T30”) to a customer cohort across multiple countries. - April 8, 2026 — A community-funded submission to Janoshik, organised by the LS Group Testing cohort, returns endotoxin across three independently-sourced vials of the January batch. EU = endotoxin units. USP <85>, the chapter on bacterial-endotoxin testing for parenteral product, does not require an undetectable result; it sets a maximum permitted endotoxin load per dose. For parenteral drugs other than intrathecal the threshold is 5 EU/kg, which for a 70 kg adult is 350 EU per dose. The relevant question is therefore not what a vial contains but what a single injection delivers.

What the numbers do and do not say. Endotoxin per vial is fixed; endotoxin per injection scales with how much of the vial you draw. On these three vials a user at the 2.5 mg starting dose receives 113–192 EU, comfortably under the 350 EU ceiling. The 1,350 and 1,360 EU vials cross the ceiling at about 7.8 mg, and the 2,306 EU vial crosses it at about 4.6 mg. Anyone titrated to 5 mg or above on the worst vial, or to 10 mg or above on any of the three, is over the limit on every injection, and the excess compounds across a weekly schedule.

Three independent vials, three independent donors, three concentrations of dilution test, all converging on the 1,350-2,306 EU/vial range. This is not measurement variance. Our corpus holds the Janoshik certificate carrying the 2,306 EU/vial result and its companion certificate from the same submission; the 1,350 and 1,360 EU/vial readings are reported in the source thread and we hold no certificate for them. A retest of the original kit was described in mid-April as being arranged; no retest result has been published as of July 31, 2026. - April 8 onwards — Community-wide “Endotoxin Warning” thread spins up on glp1forum.com (64+ posts as of mid-April). A separate “Enter your JEEP batch number and see the differences in your kit” thread starts collecting batch-by-batch reports from customers worldwide. - Mid-April 2026 — JEEP’s vendor announcement thread on the same forum has accumulated 173+ posts as community pressure for an official response builds. Vendor’s response in that thread is mostly promotional sales posts, no batch recall.

Why endotoxin matters here: endotoxins are bacterial-cell-wall lipopolysaccharides that survive most peptide-purification steps if the upstream synthesis was contaminated. They are not destroyed by standard sterile-filtration. On injection (subcutaneous, intramuscular, IV), endotoxin triggers a fever-and-inflammation response (the historical “pyrogen reaction”); at the levels reported on this batch, repeated dosing carries cumulative risk. This is the safety signal that USP <85> exists to catch.

Why this is a vendor-level event, not a one-off: the three vials were sourced from different customers’ independent purchases of the same January batch. They were not the same physical inventory. A fault that crosses customers in different countries and different dilution windows points at the upstream production lot, not the testing lab and not handling-after-shipment.

Primary sources: community safety-warning thread documenting the LS testing results; community-wide “Endotoxin Warning” discussion thread; batch-number aggregation thread; vendor announcement thread (for context on the vendor’s response posture).